HP cohorts, SAD
TEAEs
In total, 22 out of 24 (91.7%) HPs who received at least a single dose of ARO-ANG3 reported at least one TEAE, with a total of 65 reported TEAEs (Table Overall summary of TEAEs in HP cohorts receiving placebo or 35 mg, 100 mg, 200 mg or 300 mg of ARO-ANG3 (SADs) and cohorts receiving placebo or 100 mg, 200 mg or 300 mg of ARO-ANG3 (MADs)Notes: MedDRA version 21.1; related denotes possibly or probably.TEAEs reported in more than one participant are presented in Extended Data Table 